X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the acquisition, CASI gains global rights to the Cleave's clinical asset, CB-5339 tosylate, an oral, second-generation, small molecule valosin-containing protein (VCP)/p97 inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndrome.
Lead Product(s): CB-5339
Therapeutic Area: Oncology Product Name: CB-5339
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: CASI Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 20, 2023
Details:
CB-5339 is an oral second-generation, small molecule VCP/p97 inhibitor, and is currently in Phase 1 clinical trial in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms.
Lead Product(s): CB-5339
Therapeutic Area: Oncology Product Name: CB-5339
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cleave Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
First patient has been dosed with CB-5339 in a Phase 1 clinical trial of patients with relapsed/refractory acute myeloid leukemia (AML) or relapsed/refractory intermediate or high-risk myelodysplastic syndrome (MDS).
Lead Product(s): CB-5339
Therapeutic Area: Oncology Product Name: CB-5339
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
